Martin R Stockler - JoVE Visualize

Showing results (101-110 of 167) with videos related to

Pageof 17

Sort By:

Cancer Research|September 24, 2009

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profilingLiangli Zhao, Brian Y Lee, David A Brown, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancerMartin R Stockler, Felix Hilpert, Michael Friedlander, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013

The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimatesBelinda E Kiely, Andrew J Martin, Martin H N Tattersall, et al.

Journal of the National Cancer Institute|July 16, 2010

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trialPeter S Grimison, Martin R Stockler, Damien B Thomson, et al.

The Prostate|March 28, 2024

Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancerKate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.

The Lancet. Oncology|June 6, 2007

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trialMartin R Stockler, Rachel O'Connell, Anna K Nowak, et al.

Cancers|October 14, 2022

Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by SimvastatinBlossom Mak, Hui-Ming Lin, Thy Duong, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2022

177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T TherapyNikeith John, Sarennya Pathmanandavel, Megan Crumbaker, et al.

BJU International|May 24, 2021

ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.

JCO Oncology Practice|June 16, 2023

Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance RecommendationsCiara Conduit, Jeremy Lewin, Andrew Weickhardt, et al.

Pageof 17

Showing results (101-110 of 167) with videos related to

Sort By:

Pageof 17

Cancer Research|September 24, 2009

Identification of candidate biomarkers of therapeutic response to docetaxel by proteomic profilingLiangli Zhao, Brian Y Lee, David A Brown, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 2, 2014

Patient-reported outcome results from the open-label phase III AURELIA trial evaluating bevacizumab-containing therapy for platinum-resistant ovarian cancerMartin R Stockler, Felix Hilpert, Michael Friedlander, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2013

The median informs the message: accuracy of individualized scenarios for survival time based on oncologists' estimatesBelinda E Kiely, Andrew J Martin, Martin H N Tattersall, et al.

Journal of the National Cancer Institute|July 16, 2010

Comparison of two standard chemotherapy regimens for good-prognosis germ cell tumors: updated analysis of a randomized trialPeter S Grimison, Martin R Stockler, Damien B Thomson, et al.

The Prostate|March 28, 2024

Clinical validation of circulating GDF15/MIC-1 as a marker of response to docetaxel and survival in men with metastatic castration-resistant prostate cancerKate L Mahon, Sarah Im Sutherland, Hui Ming Lin, et al.

The Lancet. Oncology|June 6, 2007

Effect of sertraline on symptoms and survival in patients with advanced cancer, but without major depression: a placebo-controlled double-blind randomised trialMartin R Stockler, Rachel O'Connell, Anna K Nowak, et al.

Cancers|October 14, 2022

Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by SimvastatinBlossom Mak, Hui-Ming Lin, Thy Duong, et al.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2022

177Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing 177Lu-PSMA-I&T TherapyNikeith John, Sarennya Pathmanandavel, Megan Crumbaker, et al.

BJU International|May 24, 2021

ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.

JCO Oncology Practice|June 16, 2023

Patterns of Relapse in Australian Patients With Clinical Stage 1 Testicular Cancer: Utility of the Australian and New Zealand Urogenital and Prostate Cancer Trials Group Surveillance RecommendationsCiara Conduit, Jeremy Lewin, Andrew Weickhardt, et al.

Pageof 17